BACKGROUND: Direct-acting oral anticoagulants (DOACs) represent an alternative to
vitamin K antagonists in the treatment of venous thromboembolism (VTE); however …

Background: Obesity is a well-known risk factor for venous thromboembolism (VTE),
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …

Background: Studies of acute venous thromboembolism (VTE) and non-valvular atrial
fibrillation (AF) have shown comparable therapeutic efficacy and similar or lower bleeding …

The major practical advantage of the direct oral anticoagulants (DOACs), comprising the
thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban, edoxaban, and …

Background: Direct oral anticoagulants (DOACs) are known to have similar efficacy with a
decreased risk of bleeding when compared to warfarin for the treatment of venous …

Direct oral anticoagulants (DOACs) are commonly used oral factor Xa inhibitors in recent
years. However, in some special clinical situations, the appropriate use of these …

Introduction: Limited data exists on the safety and efficacy of direct‐acting oral
anticoagulants (DOAC) use in morbidly obese patients with venous thromboembolism …

Study Objective Studies on the use of direct oral anticoagulants (DOACs) in obese patients
are limited. Current guidelines advise against DOAC use in patients with a body weight …

Background: Anticoagulation (AC) is the cornerstone of treatment for venous
thromboembolism (VTE). Direct oral anticoagulants (DOACs) have become the standard of …

Background: Venous thromboembolism (VTE) poses a significant health risk to patients with
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …